It could be related to the fact that the majority of our pituitary irAE patients were on anti-PD-1/anti-PD-L1 therapy rather than anti-CTLA-4 therapy, which is generally associated with hypophysitis. This evidence concerns the gene CTLA4 and hypophysitis.